In contrast, anti-PD-L1-bound platelets are activated in the tumour microenvironment and release anti-PD-L1-bound EVs, which inhibit immune checkpoints in tumour tissue, thereby increasing the number of infiltrating CD8+ and CD4+ T cells within the tumour. This evidence concerns the gene CD8A and neoplasm.